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It has been accepted that receptor-mediated action of steroid hormones depends on
both the receptor and the hormonal level.  The mechanism of transcription by steroid
receptors is mediated by cofactors, which function as co-activators or co-repressors,
while their non-genomic actions depend on receptors localized to the cell membrane.
Recently, a number of environmental chemicals, which are now termed as endocrine
disruptors, have been identified, and their unwanted effects on our lives have become
serious problems all over the world.  Their adverse effects on endocrine systems in
animals, mostly estrogenic or anti-estrogenic, have resulted in reproductive malfunction
and developmental disorders.  Although aryl hydrocarbons exhibit estrogenic or anti-
estrogenic activity through specific interaction with aryl hydrocarbon receptors, other
chemicals seem to interact directly with estrogen receptors, α and β forms.  In this
paper, we surveyed the most recent understanding of endocrine disruptors from the
viewpoint of steroid receptor systems.  We suggest two potential mechanisms of action
for endocrine disruptors.  Endocrine distruptors i) directly associate with steroid
receptor systems and/or ii) associate with the growth factor or the neurotransmitter
receptor systems, and then upregulate the mitogen-activated protein kinase signaling
cascades, leading to the ligand-independent activation of steroid receptor systems.  Using
these steroid receptor-dependent mechanisms, it appears that endocrine disruptors
disorder our endocrine systems.  We have proposed future suggestions to further
understand endocrine disruptors from the viewpoint of steroid receptor systems.
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Since the cloning of human glucocorticoid re-
ceptor (Hollenberg et al., 1985), a number of
nuclear receptors including steroid receptors
have been identified (Mangelsdorf et al., 1995;
Pfaff et al., 1997), and are now understood as
transcription factors included in a nuclear re-
ceptor superfamily (Freedman, 1999).  Recent-
ly, estrogen receptors (ERs) have been shown to
localize to the cell membrane, and their role in
non-genomic actions have been demonstrated as
well (Chen et al., 1999; Goetz et al., 1999).
A number of environmental chemicals have
been identified as endocrine disruptors, and their
unwanted effects on our lives have become se-
rious problems all over the world.  At present,
their adverse effects on endocrine systems in
animals, mostly estrogenic or anti-estrogenic,
have resulted in reproductive malfunction and
developmental disorders (Keith, 1997).  Among
endocrine disruptors identified so far, aryl
hydrocarbons, dioxins, exhibit estrogenic or
anti-estrogenic activity through specific inter-
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action with aryl hydrocarbon receptors (AhRs)
(Osteen et al., 1997), while most other chemicals
seem to interact directly with the ER system.
In this paper, we give a brief overview of the
recent understanding of the receptor-mediated
actions of steroid hormones, and discuss the
receptor-mediated actions of endocrine disrup-
tors.
Recent advances in the
mechanism of action of steroids
Nuclear receptors including steroid receptors
have been understood as transcription factors,
which mediate extracellular signals to the
nucleus.  A carboxy-terminus region of steroid
receptors, the ligand binding domain (LBD), spe-
cifically interacts with cognate ligands, while
the AF-2 domain recruits cofactors (Freedman,
1999; also see Fig. 1).  Once associated with es-
trogens, ER is activated and recruits co-acti-
vators such as those from the SRC-1 family and
TIF2/GRIP1/NCoA2, to interact with the estro-
gen responsive element (ERE) in responsive
genes (McKenna and O’Malley, 2000; Freedman,
1999).  When bound by an estrogen antagonist,
ER recruits N-Cor and SMRT, co-repressors,
and inhibits the transcription of estrogen respon-
sive genes (McKenna and O’Malley, 2000).  The
concept of ER-dependent genomic actions has
been accepted for other steroid receptor sys-
tems.  Recently, growth factors, neurotrans-
mitters and cyclins have been demonstrated to
crosstalk with steroid receptor systems.  Epi-
dermal growth factor (EGF), insulin-like
growth factor (IGF) (Kato et al., 1995; Bunone
et al., 1996) and dopamine (Mani et al., 1994)
could activate ERα via the mitogen-activated
protein (MAP) kinase pathway in a ligand-
independent manner.  Cyclins directly interact
with the unliganded ERα (Zwijsen et al., 1997).
Progesterone receptor (PR) is also activated by
dopamine through cAMP-dependent phospho-
rylation, and associates with SRC-1e, a co-
activator specific for PR, to interact with the pro-
gestin responsive element (PRE) (Bai et al.,
1997; Brossens et al., 1999).  On the other hand,
Fig. 1.  Mechanism of action of steroid hormones and endocrine disruptors.  A: Genomic  action.  Steroid
hormones and endocrine disruptors diretly interact with intracellular steroid receptors.  This leads to the
recruitment of cofactors for specific interaction with hormone responsive elements (HREs) in hormone re-
sponsive genes.  On the other hand, endocrine disruptors interact with receptors for growth factors or neuro-
transmitters to up-regulate mitogen-activated protein (MAP) kinase signaling.  This leads to the ligand-
independent activation of steroid receptors for the association with cofactors as described above.  B: Non-
genomic action.  Steroid hormones and endocrine disruptors associate with steroid receptors localized to the
cell membrane.  This leads to the intracellular signaling pathways.
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androgen receptor (AR) is activated by EGF,
IGF and keratinocyte growth factor (KGF)
through MAP kinase cascades, and binds to AP-
1 and Ets, a co-activator specific for AR, to
interact with the androgen responsive element
(ARE) (Klocker et al., 1999; Culig et al., 1994).
Along with the ligand-dependent and the
ligand-independent genomic actions, non-
genomic actions through the plasma membrane
receptor have recently been demonstrated to
play impotant roles in hormone responsive cells
(Chen et al., 1999; Goetz et al., 1999).  In sum-
mary, the steroid receptor system is not only a
ligand-induced transcriptional enhancer, but
also a mediator of common intracellular signal-
ing pathways in multiple cell types.
Endocrine disruptors
and the mechanism of action
Adverse effects of pharmaceuticals, industrial
waste and environmental pollutants (now all
acknowledged as endocrine disruptors) on our
lives have become a serious problem in the
world.  They disorder the endocrine system in
animals directly or indirectly.  It is obvious that
they exert their effects in a receptor-dependent
manner (Brouwer et al., 1998; Chia, 2000;
Fenner-Crisp, 2000).
Endocrine disruptors, which seemed to be
closely related to ER systems, could be classi-
fied into three groups:  estrogen mimics, anti-
estrogens and anti-androgens (Sonnenschein
and Soto, 1998; Gray et al., 1999a).  An initial
target for these compounds is ER (Nishikawa et
al., 1999).  Diethylstilbesterol (DES), a synthe-
tic estrogen, behaves as an estrogen agonist
(Hunter et al, 1999), and exposure to DES dur-
ing the fetal period induces urogenital abnor-
malities in males (Kuiper et al., 1998; Spearow
et al., 1999), oligospermia (Krishnan et al.,
1993; Vom Saal et al., 1997), the increased
incidence of undescended  testis (Kuiper et al.,
1998; Spearow et al., 1999) and hypertrophy of
the prostate (Newbold, 1995).  Polycyclic
aromatic hydrocarbons (PAHs) have an anti-
estrogenic activity through AhR (Brouwer et
al., 1998; Safe et al., 1998; Loaiza-Perez et al.,
1999), and decrease the estrogen level in the
blood (Kohn et al., 1993; Alvarez et al., 2000),
the ER level in the uterus (De Vito et al., 1992;
Alvarez et al., 2000) and the number of matured
follicles associated with the upregulation of the
follicle-stimulating hormone (Alvarez et al.,
2000).  Endocrine disruptors, which seemed to
be closely related to AR systems are Flutamide,
vinclozolin, p,p'-DDE and procymidone, anti-
androgens, which disorder prostate maturation
(Gray et al., 1999b), and induce undescended
testis (Gray et al., 1999b), hypospadia (Gray et
al., 1999b; Ostby et al., 1999) and permanent
nipples (Gray et al., 1999b; Ostby et al., 1999)
during sex differentiation.  In adult animals,
anti-androgens increase the serum levels of
androgens, luteinizing hormone and estrogens
(Ladics et al, 1998; Monosson et al., 1999), and
induces spontaneous abortions, stillbirths,
reproductive malfunction, neuroendocrine
alteration, and disorder of immune systems
(Goldman, 1997; Palanza et al, 1999; Alvarez et
al., 2000).
As demonstrated above, disorder of steroid
receptor-mediated signaling systems by endo-
crine disruptors leads to abnormal conditions in
animal physiology.  It is important to note that
some endocrine disruptors exhibit potential
activities:  (i) to interact directly with endoge-
nous steroids, (ii) to inhibit steroid receptor
binding, non-competetively or (iii) to destroy
receptor molecules or endogenous steroids
(Sonnenschein and Soto, 1998; Soto et al.,
1998).
Conclusion
Ligand-dependent and -independent signaling
pathways by steroid receptors seem to provide
insights into the understanding of the molecular
basis of endocrine disruptors as summarized in
Fig. 1.  We also summarized representative en-
docrine disruptors identified so far in Table 1.
Although a number of endocrine disruptors in
our daily lives have been identified, little is
known about their molecular basis.  It becomes
an urgent subject to further understand the mo-
lecular basis of the diverse actions of endocrine
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disruptors.  Understanding endocrine disruptors
from the viewpoint of steroid receptor-mediated
signaling may allow us to overcome these glob-
al problems.  In addition, it is obviously impor-
tant to keep up international cooperation.
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